AdipoRon and Pancreatic Ductal Adenocarcinoma: a future perspective in overcoming chemotherapy-induced resistance?
AdipoRon
PDAC
gemcitabine
resistance
Journal
Cancer drug resistance (Alhambra, Calif.)
ISSN: 2578-532X
Titre abrégé: Cancer Drug Resist
Pays: United States
ID NLM: 101738710
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
03
2022
revised:
19
04
2022
accepted:
25
05
2022
entrez:
30
9
2022
pubmed:
1
10
2022
medline:
1
10
2022
Statut:
epublish
Résumé
The latest scientific knowledge has provided additional insights accountable for the worst prognosis for pancreatic ductal adenocarcinoma (PDAC). Among the causative factors, the aptitude to develop resistance towards approved medications denotes the master key for understanding the lack of improvement in PDAC survival over the years. Even though several compounds have achieved encouraging results at preclinical stage, no new adjuvant agents have reached the bedside of PDAC patients lately. The adiponectin receptor agonist AdipoRon is emerging as a promising anticancer drug in different cancer models, particularly in PDAC. Building on the existing findings, we recently reinforced its candidacy in PDAC cells, proposing AdipoRon either as a suitable partner in gemcitabine-based treatment or as an effective drug in resistant cells. Crossing the current state-of-the-art, herein we provide a critical perspective on AdipoRon to figure out whether this receptor agonist can potentially be considered a future therapeutic choice in overcoming chemotherapy-induced resistance, expressly in PDAC.
Identifiants
pubmed: 36176754
doi: 10.20517/cdr.2022.34
pmc: PMC9511794
doi:
Types de publication
Journal Article
Langues
eng
Pagination
625-636Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
All authors declared that there are no conflicts of interest.
Références
Biomedicines. 2020 Aug 03;8(8):
pubmed: 32756381
Biomedicines. 2021 Apr 06;9(4):
pubmed: 33917380
Int J Mol Sci. 2020 Feb 12;21(4):
pubmed: 32059381
EBioMedicine. 2019 Jun;44:403-418
pubmed: 31103629
J Natl Cancer Inst. 2013 Jan 16;105(2):95-103
pubmed: 23243202
Ann Pancreat Cancer. 2020 May;3:
pubmed: 33294843
Nature. 2014 Oct 30;514(7524):628-32
pubmed: 25119024
Nutrients. 2021 Apr 02;13(4):
pubmed: 33918360
Oncoscience. 2020 Sep 9;7(9-10):76-80
pubmed: 33195739
JAMA. 2021 Sep 7;326(9):851-862
pubmed: 34547082
Arch Physiol Biochem. 2020 Feb;126(1):67-73
pubmed: 30451000
Biosci Rep. 2020 Jul 31;40(7):
pubmed: 32677676
Oncotarget. 2017 Aug 3;8(49):85378-85391
pubmed: 29156726
Eur J Cell Biol. 2021 Sep-Nov;100(7-8):151183
pubmed: 34798557
Biochem Pharmacol. 1992 Nov 3;44(9):1819-27
pubmed: 1449536
Semin Cancer Biol. 2022 Jul;82:184-196
pubmed: 33737108
Pancreatology. 2021 Apr;21(3):522-529
pubmed: 33516629
Diagnostics (Basel). 2022 Jan 23;12(2):
pubmed: 35204377
Curr Opin Gastroenterol. 2019 Sep;35(5):440-447
pubmed: 31343416
Diabetes Metab Syndr Obes. 2019 Feb 25;12:275-284
pubmed: 30881070
J Oncol. 2020 Jan 22;2020:7262479
pubmed: 32411241
Nature. 2013 Nov 28;503(7477):493-9
pubmed: 24172895
Br J Nutr. 2006 Oct;96(4):691-6
pubmed: 17010228
Am J Physiol Endocrinol Metab. 2014 Apr 1;306(7):E748-55
pubmed: 24473435
Cancers (Basel). 2021 Nov 17;13(22):
pubmed: 34830914
Surgery. 2009 Aug;146(2):258-63
pubmed: 19628082
Mediators Inflamm. 2019 Sep 9;2019:2153934
pubmed: 31582896
Cancer Res. 1992 Feb 1;52(3):533-9
pubmed: 1732039
Mol Med Rep. 2017 Jan;15(1):502-506
pubmed: 27959400
Diabetes. 2009 Jul;58(7):1616-24
pubmed: 19401420
Oncotarget. 2014 Jul 15;5(13):4732-45
pubmed: 25051362
Oncol Rev. 2020 Jul 06;14(2):448
pubmed: 32676170
Dig Dis Sci. 2014 Jun;59(6):1192-6
pubmed: 24801685
Cancer Causes Control. 2009 Jul;20(5):625-33
pubmed: 19051043
Crit Rev Oncol Hematol. 2017 Jun;114:139-152
pubmed: 28477742
J Cyst Fibros. 2008 May;7(3):244-51
pubmed: 18068553
Cell Biosci. 2021 Apr 26;11(1):77
pubmed: 33902691
Int J Cancer. 2012 May 15;130(10):2428-37
pubmed: 21681743
Int J Clin Exp Med. 2015 May 15;8(5):8094-100
pubmed: 26221375
Cancer Drug Resist. 2020 May 11;3(3):491-520
pubmed: 35582441
Br J Cancer. 2020 Aug;123(4):644-656
pubmed: 32493992
Int J Cancer. 2021 Apr 1;148(7):1625-1636
pubmed: 33038280
Pharmacogenomics. 2013 Jul;14(9):1047-51
pubmed: 23837479
Front Pharmacol. 2022 Feb 22;13:837503
pubmed: 35273510
Cancer Drug Resist. 2020 Oct 12;3(4):819-831
pubmed: 35582220
Sci Rep. 2021 Feb 3;11(1):2923
pubmed: 33536560
Cancer Lett. 2013 Jun 10;333(2):152-8
pubmed: 23340176
Surg Oncol. 2021 Sep;38:101582
pubmed: 33892432
Front Endocrinol (Lausanne). 2019 Aug 13;10:539
pubmed: 31456747
Bratisl Lek Listy. 2017;118(7):394-398
pubmed: 28766348
Biochem Biophys Res Commun. 2004 Aug 13;321(1):154-60
pubmed: 15358228
Cancer Drug Resist. 2020;3:572-585
pubmed: 33073205
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Int J Biol Sci. 2019 Jan 1;15(2):253-264
pubmed: 30745818
Cell Mol Life Sci. 2021 Jul;78(14):5505-5526
pubmed: 34131808
Biochem Biophys Res Commun. 2007 Jul 13;358(4):1091-5
pubmed: 17521614
Eur J Cancer. 2020 Jan;125:83-93
pubmed: 31841792
Nat Rev Endocrinol. 2022 Feb;18(2):79-80
pubmed: 34893788
Front Cell Dev Biol. 2021 May 20;9:637675
pubmed: 34095111
Best Pract Res Clin Endocrinol Metab. 2014 Jan;28(1):43-58
pubmed: 24417945
Int J Mol Sci. 2021 May 25;22(11):
pubmed: 34070338
Cancer Drug Resist. 2021 Oct 8;4(4):904-922
pubmed: 35582381
Diabetes Metab. 2014 Nov;40(5):363-72
pubmed: 24986510
Oncogene. 2014 Jul 17;33(29):3812-9
pubmed: 23995783
EBioMedicine. 2021 Apr;66:103327
pubmed: 33862582
BMC Cancer. 2019 Jan 8;19(1):40
pubmed: 30621618
Biomed Pharmacother. 2020 Jan;121:109521
pubmed: 31689601
Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188461
pubmed: 33157162
N Engl J Med. 2018 Dec 20;379(25):2395-2406
pubmed: 30575490
Metabolism. 2011 Dec;60(12):1664-72
pubmed: 21632069
Cancers (Basel). 2021 Oct 10;13(20):
pubmed: 34680216
Front Oncol. 2020 Oct 15;10:576399
pubmed: 33178608
Carcinogenesis. 2021 Apr 30;42(4):546-556
pubmed: 33624791
J Physiol Pharmacol. 2015 Oct;66(5):653-63
pubmed: 26579571
Oncol Lett. 2021 May;21(5):369
pubmed: 33747225
Cell Death Dis. 2018 Jul 23;9(8):804
pubmed: 30038429
Pharmacology. 2021;106(3-4):143-153
pubmed: 32966993
Cell Rep Med. 2020 Nov 17;1(8):100143
pubmed: 33294863
Front Pharmacol. 2021 Apr 19;12:648407
pubmed: 33953682
Cell Death Dis. 2022 Feb 4;13(2):114
pubmed: 35121743